GlassScriptPhysician profile
Murad C Assaad
NPI 1912265109
$139,037.47
in general payments reported to CMS, 2019-2025
50 companies · $120K in 2025
The $120K reported for 2025 was more than what 99% of Sleep Medicine (Internal Medicine) providers received nationally (typical 2025 total: $447).
See the full distribution for Sleep Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $486 · 2020: $162 · 2021: $528 · 2022: $1,150 · 2023: $1,213 · 2024: $15K · 2025: $120K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $42K · Honoraria: $40K · Consulting Fee: $28K · Travel and Lodging: $19K · Food and Beverage: $6,055 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $975 · Education: $63.01.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $42,446.00 |
| Honoraria | $39,750.00 |
| Consulting Fee | $28,432.50 |
| Travel and Lodging | $18,989.92 |
| Food and Beverage | $6,055.25 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $975.00 |
| Education | $63.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avadel Cns Pharmaceuticals, LLC | $83,262.95 | 2024-2025 | Lumryz |
| Axsome Therapeutics, INC. | $46,122.28 | 2022-2025 | Sunosi |
| Jazz Pharmaceuticals INC. | $5,191.50 | 2019-2024 | Xywav |
| Inspire Medical Systems, INC. | $429.19 | 2023-2025 | Inspire |
| Harmony Biosciences LLC | $418.25 | 2020-2025 | Wakix |
| Abbott Laboratories | $403.36 | 2021-2025 | Freestyle Libre 3 |
| Mannkind Corporation | $260.06 | 2019-2025 | Afrezza |
| Dexcom, INC. | $230.26 | 2021-2025 | Dexcom G6 Transmitter |
| Amgen INC. | $209.63 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $200.53 | 2022-2024 | Austedo Xr, Austedo, Ajovy |
| Novo Nordisk INC | $181.35 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Idorsia Pharmaceuticals US INC | $177.42 | 2022-2023 | Quviviq |
| Ucb, INC. | $161.45 | 2023-2025 | Zilbrysq, Rystiggo |
| Corcept Therapeutics | $161.09 | 2021-2025 | Korlym |
| Medtronic, INC. | $136.47 | 2024-2025 | Minimed 780g, Intellis Adaptivestim |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Murad Assaad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.